{
    "organizations": [],
    "uuid": "db8d2a85dc556af981870eaa7158b7f9c3eeeaf9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bayer-rolling-submission-of-new-dr/brief-bayer-rolling-submission-of-new-drug-application-in-us-for-larotrectinib-completed-idUSFWN1R80GZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Bayer: Rolling Submission Of New Drug Application In US For Larotrectinib Completed",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - BAYER AG:\n* ‍ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION IN U.S. FOR LAROTRECTINIB FOR TREATMENT OF TRK FUSION CANCER​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-26T18:47:00.000+03:00",
    "crawled": "2018-03-27T11:51:22.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "bayer",
        "ag",
        "completion",
        "rolling",
        "submission",
        "new",
        "drug",
        "application",
        "larotrectinib",
        "treatment",
        "trk",
        "fusion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}